ReNAgade Therapeutics Secures $300 Million Series A Funding to Revolutionize RNA Medicine

Cambridge, MA, May 23, 2023 (Business Wire) -- ReNAgade Therapeutics, a cutting-edge company focused on harnessing the full potential of RNA medicines for disease correction, has successfully raised $300 million in a Series A financing round led by MPM BioImpact and F2 Ventures. Built on innovative delivery technologies and an all-RNA platform, ReNAgade aims to overcome limitations in RNA therapeutics by expanding the reach of RNA medicines to previously inaccessible tissues and cells.

Read full article here.